Context: GH deficiency (GHD) in adults is associated with a cluster of cardiovascular risk factors that may contribute to an increased mortality for cardiovascular disease.
T HE PRIMARY GOAL of GH replacement in children is
to promote linear growth and to normalize final height to within or above the genetic target. GH has, however, other important physiological functions that influence several key metabolic processes, body composition, muscle strength, and bone mineral density. It is now established that adults with GH deficiency (GHD) may develop a cluster of cardiovascular risk factors, including unfavorable lipid profile, increased body fat, premature atherosclerosis, decreased fibrinolytic activity, increased peripheral insulin resistance (1, 2) , as well as reduced cardiac performance (3, 4) , all of which may contribute to a reduced life expectancy with an increased mortality for cardiovascular disease (CVD) (5) .
In adolescents with severe GHD, there is increasing evidence that suggests that the discontinuation of GH replacement therapy at completion of linear growth may result in adverse effects on body composition, lipid profile, bone mineral density, cardiac morphology, and performance. However, there is still debate as to whether these abnormalities may predispose these patients to increased cardiovascular morbidity (6 -9) . The possibility that these changes may be a result of reversal of supraphysiological serum IGF-I due to the high GH doses used in some cases (6) should also be considered.
In contrast, relatively few studies have investigated whether or not children with GHD have metabolic and cardiac abnormalities that may place them at a higher risk of CVD at an early age. In the majority of these studies, lipoproteins in children with GHD are normal at baseline, but a beneficial effect of GH on lipid profile is observed during treatment (10 -14) . In addition, GH therapy reduces plasma homocysteine levels, which are increased in children with GHD (14, 15) . Elevated plasma homocysteine levels are considered to be independent risk factors for CVD.
Only a few studies have investigated the effect of GHD and GH replacement therapy on cardiac performance in children with GHD (16 -18) . GHD in children was associated with reduced cardiac mass, which increased after 1 yr of GH replacement therapy (17, 18) . Conversely, neither GHD nor GH replacement was associated with alteration of cardiac function in children (17, 18) .
The existing evidence indicates that atherosclerotic CVD begins in childhood (19, 20) . In children, obesity occurs with other risk factors for CVD, such as increased blood pressure, adverse changes in serum lipoproteins, and hyperinsulinemia, leading to acceleration of atherosclerotic lesion; therefore, the primary prevention of atherosclerotic CVD should begin in childhood.
The aim of this observational, open, prospective, casecontrol study was to investigate the cardiovascular risk of GHD in prepubertal children. Therefore, cardiac mass and function, lipid profile, and degree of insulin resistance were evaluated in children with GHD before and after 1 and 2 yr of GH replacement therapy and in age-, sex-, pubertal status-, body surface area-, and body mass index (BMI)-matched controls before and 1 and 2 yr of observation. Moreover, to investigate whether the severity of GHD was also correlated with the degree of cardiac and metabolic impairment, children were divided in two groups on the basis of GH response at stimulation tests.
Patients and Methods Patients
Thirty prepubertal children with GHD (18 boys and 12 girls) aged 9.3 Ϯ 0.5 yr (range, 6.0 -11.5 yr) were enrolled in the study. GHD was diagnosed according to clinical and auxological criteria (21) and by peak GH concentrations Ͻ10 g/liter after two stimulation tests (mean peak GH after clonidine, 4.5 Ϯ 0.5 g/liter; after arginine, 3.5 Ϯ 0.4 g/liter). Twenty-seven children had isolated GHD; three had multiple pituitary hormone deficiency, and these children were receiving stable replacement with l-thyroxin, hydrocortisone, and 1-desamino-8-d-arginine vasopressin as necessary, before GHD was investigated. Magnetic resonance imaging of the hypothalamus-pituitary region documented pituitary hypoplasia in nine patients, ectopic posterior pituitary with stalk hypoplasia in five, empty sella in four, pituitary cyst in two, and craniopharyngioma in one. Before entry in the study, none of the patients received GH replacement. Previous or current CVD, respiratory, renal, or endocrine disease, or family history of CVD were exclusion criteria for entering the study.
Patients' profile at study entry is summarized in Table 1 . Height and target height (sex-corrected midparental height) were expressed as sd score (SDS) according to the standards of Tanner (22) .
Controls
Thirty healthy children (18 boys), age, sex, pubertal status, body surface area, BMI, socioeconomic status, and geographic area matched with the patients, were enrolled in the study as controls. As for the patients, previous or current CVD respiratory, renal, or endocrine disease, or history of CVD were exclusion criteria.
Study protocol
At study entry, all subjects underwent measurement of height, weight, heart rate, systolic (SBP) and diastolic (DBP) blood pressure, serum IGF-I, total cholesterol, high-density lipoprotein (HDL)-cholesterol, triglycerides, glucose and insulin levels, and echocardiography. We calculated the atherogenic index (AI) as the ratio of total/HDL cholesterol, considered as an index of severe cardiovascular risk (23) . Low-density lipoprotein (LDL)-cholesterol was calculated using the Friedewald formula (24) . Insulin resistance was evaluated by the homeostasis model assessment (HOMA) score, by applying the formula of Matthews et al. (25) [fasting serum insulin (microunits per milliliter) ϫ fasting plasma glucose (millimoles per liter) /22.5] .
In children with GHD, the evaluation of these parameters was also repeated after 1 and 2 yr of GH replacement therapy, whereas in controls evaluation was repeated after 1 and 2 yr of follow-up. Children with GHD were treated with a 30 g/kg⅐d dose of GH (21) .
To investigate whether the severity of GHD was correlated with the degree of cardiac impairment, children were divided in two groups on the basis of GH peak after stimulation tests. The group with severe GHD (n ϭ 13) was characterized by a GH peak less than 5 g/liter at both stimulation tests (range, 0.3-4.9 g/liter); the group with partial GHD (n ϭ 17) was characterized by a GH peak concentration above 5 g/liter at one or both stimulation tests (range, 5.0-9.5 g/liter). Informed parental consent to participate in the study was obtained for both patients and controls.
Echocardiography
M-mode, two-dimensional, and pulsed Doppler echocardiographic studies were performed with ultrasound systems (Sonos 2000; Agilent Technologies, Andover, MS) using a 3.5-mHz transducer, during at least three consecutive cardiac cycles. The records were made by two investigators (L.S. and V.F.) blind in respect to the patients' status. All patients were studied in the left lateral recumbent position after a 10 min resting period according to the recommendations of the American Society of Echocardiography (26) . The following measurements were recorded: interventricular septum thickness (IST), left ventricular (LV) posterior wall thickness (LVPWT), and LV end-systolic (LVESD) and end-diastolic (LVEDD) diameter; LV end-diastolic volume (LVEDV) and end-systolic volume (LVESV) were calculated according to the Simpson algorithm (27) . The LV ejection fraction (LVEF) was calculated using the following formula: LVEF% ϭ (LVEDV Ϫ LVESV)/LVEDV ϫ 100. The fractional shortening (FS) percentage was calculated using the following formula: 
Data are expressed as mean Ϯ SE. NS, Not significant; M, male; F, female.
FS% ϭ (LVEDD Ϫ LVESD)/LVEDD ϫ 100. The LV mass (LVM) was calculated by using Devereux's formula according to Penn's convention with the regression-corrected cube formula LVM ϭ 1.04[(ISV ϩ LVEDD ϩ PWT) 3 Ϫ (LVEDD) 3 ] Ϫ 13.8 g, and expressed by LVM index (LVMi) after correction for BSA. Doppler studies provided indexes of ventricular filling that were derived from the mitral flow velocity curves, i.e. maximal early diastolic flow velocity (E in centimeters per second), maximal late diastolic flow velocity (A in centimeters per second), and the ratio between E and A curves (E/A, normal value Ͼ1); the isovolumetric relaxation time (IRT), which represents the interval between the end of aortic valve closure and the onset of mitral valve opening, was also evaluated.
Assays
Serum GH levels were measured by immunoradiometric assay using commercially available kits (HGH-CTK-IRMA; Sorin, Saluggia, Italy). The sensitivity of the assay was 0.2 g/liter. The intraassay and interassay coefficients of variation were 4.5 and 7.9%, respectively. Plasma IGF-I was measured using two-site immunoradiometric assay kit (Diagnostics System Laboratories, Webster, TX). Values were expressed as SDS according to the normative data provided by the manufacturer. The IGF-I intraassay and interassay coefficients of variation were 3.4 and 8.2% respectively.
Statistical analysis
All data are reported as mean Ϯ sem unless otherwise specified. The statistical analysis was performed by a package from SPSS (Chicago, IL). All of the variables evaluated in our study have been screened for normality before statistical analysis; skewness and kurtosis have been estimated for all variables, and in no case did these parameters suggest a major deviation from normality, because a Kolmogorov-Smirnov test of normality did not show significant deviation from normality.
Comparisons between patients and controls, patients with severe and those with partial GHD, and between males and females with GHD were performed by paired or unpaired Student's t test as appropriate.
To evaluate differences between repeated measurements before and during GH treatment in GHD patients and over time taking into account the correlation from within subject's data, a generalized linear model for repeated-measures ANOVA was adopted. The F test provides the estimate of the differences over time and treatment with respect to baseline. Linear component over time has also been estimated. This method does incorporate dependency within an experimental unit and compare contrasts among groups, not raw values.
Pearson's correlation coefficient was calculated to test the relationship between variables. Significance was set at 5%.
Results
Clinical, hormonal, and cardiovascular parameters in controls and in GHD patients at baseline and during GH replacement therapy are reported in Table 2 . At study entry, height and serum IGF-I, as expected, were significantly lower in GHD subjects than in healthy children (P Ͻ 0.0001). During years 1 and 2 of GH therapy, both height (P Ͻ 0.0001) and serum IGF-I (P Ͻ 0.0001) significantly increased, becoming similar to the control group.
Cardiac morphology and function
At study entry, heart rate, SBP, and DBP were similar in the two groups. During years 1 and 2 of GH therapy, heart rate, SBP, and DBP remained unchanged.
As shown in Table 2 , LVPWT, LVEDD, and LVMi were significantly reduced in GHD children compared with controls (P Ͻ 0.002). LV systolic function, measured by FS and LVEF, and diastolic function, measured by E/A ratio and IRT, were similar in GHD children and controls. IST, LVPWT, LVESD, LVEDD, and LVMi significantly increased during the first year of GH therapy compared with pretreatment values (P Ͻ 0.0001) and then remained unchanged during the second year of GH replacement. LV systolic performance and diastolic filling did not change significantly during treatment (Table 2) . After 2 yr, LVMi in children with GHD was similar to that measured in controls; none of the patients developed cardiac hypertrophy. The increase of LVMi was significantly correlated with the increase of IGF-I levels (r ϭ 0.63; P Ͻ 0.0001).
No significant differences were observed in cardiac morphology and function between males and females with GHD both at baseline (LVMi,
Metabolic and lipid profile
At baseline BMI, lipid profile, fasting blood glucose and insulin levels, as well as HOMA index were comparable with those recorded in the control group (Table 3) . After 2 yr of GH replacement therapy, BMI remained unchanged and total cholesterol and AI significantly decreased compared with both pretreatment (P Ͻ 0.007 and P Ͻ 0.0001, respectively) and control (P Ͻ 0.0001 and P Ͻ 0.03, respectively) values. The decrease in AI was significantly correlated with the increase in IGF-I levels (r ϭ Ϫ0.26; P Ͻ 0.05). A mild increase in fasting insulin levels and HOMA index was observed, both values being higher than baseline (P Ͻ 0.001 and P Ͻ 0.0001, respectively) and control (P Ͻ 0.01) values after 2 yr of GH therapy. These values were, however, within the normal range for age (28) .
No significant differences between males and females with GHD were observed in metabolic parameters at baseline and after GH replacement therapy (data not shown). AI decreased from 3.5 Ϯ 0.2 to 2.4 Ϯ 0.1 (P Ͻ 0.005) in males and from 3.6 Ϯ 0.3 to 2.4 Ϯ 0.1 (P Ͻ 0.0001) in females after 2 yr of GH treatment, whereas a mild increase in HOMA index was observed compared with baseline values in both males (from 0.7 Ϯ 0.07 to 1.8 Ϯ 0.2; P Ͻ 0.003) and females (from 0.8 Ϯ 0.1 to 2.3 Ϯ 0.3; P Ͻ 0.009).
Cardiovascular and metabolic findings in children with severe GHD
In 13 children with severe GHD, LVPWT (5.1 Ϯ 0.3 mm), LVESD (20.8 Ϯ 0.5 mm), LVEDD (34.4 Ϯ 0.8 mm), and LVMi (46.3 Ϯ 1.6 g/m 2 ) were significantly reduced compared with the 17 children with partial GHD (LVPWT, 5.7 Ϯ 0.9 mm, P Ͻ 0.04; LVEDS, 22.9 Ϯ 0.8 mm, P Ͻ 0.03; LVEDD, 36.7 Ϯ 0.8 mm, P Ͻ 0.05; LVMi, 53.0 Ϯ 2.2 g/m 2 , P Ͻ 0.03). The LVMi was, however, significantly reduced also in the group with partial GHD compared with controls (60.3 Ϯ 2.5 g/m 2 ; P Ͻ 0.005) (Fig. 1) . Cardiac function was similar in children with severe or partial GHD (data not shown). At baseline, HDL cholesterol (1.2 Ϯ 0.1 vs. 1.5 Ϯ 0.1 mmol/liter; P Ͻ 0.02) was lower in children with severe than in those with partial GHD, whereas AI (3.7 Ϯ 0.3 vs. 3.0 Ϯ 0.1; P Ͻ 0.03) was significantly higher in children with severe than in those with partial GHD. A significant decrease in AI was observed during GH replacement in both children with severe GHD (to 3.0 Ϯ 0.3 after 1 yr and to 2.6 Ϯ 0.3 after 2 yr; P Ͻ 0.01) and partial GHD (to 2.5 Ϯ 0.2 after 1 yr and to 2.3 Ϯ 0.1 after 2 yr; P Ͻ 0.0001) (Fig. 2) . At study entry, the HOMA index was comparable with controls (0.8 Ϯ 0.3) in both severe GHD (0.8 Ϯ 0.4) and partial GHD (0.6 Ϯ 0.1) children. During GH treatment, the HOMA index increased more significantly in the group with partial GHD (to 1.4 Ϯ 0.4 after 1 yr and to 2.2 Ϯ 0.4 after 2 yr of GH; P Ͻ 0.003). After 2 yr of therapy, the HOMA index was higher in the group with partial GHD than in controls (0.9 Ϯ 0.3; P Ͻ 0.02), although the increase was not statistically significant compared with children with severe GHD (1.3 Ϯ 0.2; P Ͻ 0.08) (Fig. 3) . At 2 yr, the dose of GH received by children with partial GHD (35 Ϯ 0.8 g/kg⅐d) was higher than that received by the group with severe GHD (30 Ϯ 1.0 g/kg⅐d; P Ͻ 0.002).
Discussion
A large number of studies have documented that adults (1-5) as well as adolescents (6 -8, 29) with severe GHD have a cluster of cardiovascular risk factors that could place them at a higher risk of cardiovascular morbidity. It is now established that atherosclerotic CVD begins in childhood (19, 20) . Relatively few studies, however, have investigated whether GHD in children is associated with increased risk factors for CVD. Shulman et al. (17) in a prospective, uncontrolled, study enrolling 10 children with GHD documented a reduced LVM that significantly increased after 1 yr of GH therapy, whereas cardiac function was not modified. The major drawback of the study by Shulman et al. was the lack of a control group. In a previous short-term case-control study (18) , we also demonstrated that heart size was significantly reduced in 12 GHD children and increased significantly after 1 yr of GH replacement.
The results of the current observational, open, prospective, case-control study further support the evidence of a significant reduction in cardiac size without changes of cardiac function in children with GHD. One year of GH replacement normalizes IGF-I levels and cardiac mass, and prolonged GH replacement for 2 yr does not further modify cardiac mor- 1 . Mean Ϯ SEM measurements of the LVMi, before and during 2-yr GH therapy, in children with severe GHD compared with children with partial GHD and controls. *, P Ͻ 0.03 comparing children with severe vs. partial GHD at study entry. §, P Ͻ 0.005 comparing both children with severe and partial GHD vs. controls at study entry.
FIG. 2. Mean
Ϯ SEM values of AI in children with severe GHD compared with children with partial GHD and controls, before and during 2-yr GH therapy. *, P Ͻ 0.03 comparing children with severe vs. partial GHD at study entry. §, P Ͻ 0.01 analyzing the effect of GH treatment during the study in the group with severe GHD. #, P Ͻ 0.0001 analyzing the effect of GH treatment in the group with partial GHD.
phology and function. Therefore, replacement GH treatment, in the dose of 30 g/kg⅐d, does not have any hypertrophic effect on the heart. In a previous study on 14 adolescents with partial GHD, Radetti et al. (16) reported that LVM and systolic and diastolic functions did not differ from a control group after 1 yr of GH therapy at a relatively high dose of GH (44 g/kg⅐d). After 5 yr of GH treatment, however, an increase in LVM and a mild impairment in LV diastolic function was observed (16) . The major drawback of that study was the lack of baseline data. The different results with respect to the present study may depend on different GH dosages, duration of GH treatment, and degree of GHD. In particular, the different degree of GHD may result in a different response to GH replacement, which might ultimately result in a varied increase in cardiac size. The results of the present study indicate that children with severe GHD have a more evident reduction in LVM than children with partial GHD, although in both groups LVM was significantly reduced compared with controls. Using a standard dose of GH, we did not observe any different response between the two groups. After 2 yr of GH replacement, severe GHD, partial GHD, and controls had similar cardiac size. Altogether, these results indicate that GH, directly or indirectly through IGF-I, is not only involved in the regulation of somatic growth in children but also in cardiac growth, probably through the modulation of the size of cardiomyocytes (30) .
We did not observe significant gender-related differences on cardiac mass and function both at baseline and in the long-term effects of GH replacement therapy.
Several studies have investigated plasma lipoproteins in children with GHD, providing conflicting results (10, 11, (13) (14) (15) . In adults with untreated GHD and in adolescents with severe childhood-onset GHD at discontinuation of GH, the most common lipid pattern is represented by increased total and LDL cholesterol and decreased HDL cholesterol levels, increased triglycerides, and AI (1, 7, 8, 31) . Conversely, the majority of the studies in children with GHD failed to find abnormalities in the lipid profile at baseline (10, 11, (13) (14) (15) . The difference between adults and children with GHD may reflect the population trend for a rise in cholesterol and LDL cholesterol with increasing age.
In the present study, as in our previous studies (14, 18), we did not find any difference in lipid profile between GHD children and controls at baseline. During 2 yr of GH treatment, we observed an improvement in lipid profile, with a significant decrease in total cholesterol and in AI compared with both the baseline and the control levels. In agreement with others (12), we did not observe significant gender-related differences in the long-term effects of GH replacement therapy.
This beneficial effect of GH treatment on AI has been reported in other short-and long-term studies evaluating the efficacy of GH therapy on lipid profile in GHD children (10 -12, 14) . In a 6 yr follow-up study, van der Sluis et al. (13) documented a long-term beneficial effect of GH therapy on AI, as well as on HDL cholesterol in GHD children. It is well known that abnormalities in lipid profile may severely increase the coronary risk of GHD patients (32) ; thus, the decrease in the total/HDL cholesterol ratio during GH therapy can be clinically relevant to the prevention of CVD in midlife, because it represents one of the most efficient predictors of coronary heart disease in adults (33) .
The exact mechanisms that underlie these changes are not fully understood, but GH may act through the regulation of both the activity of the cholesterol 7 ␣-hydroxylase enzyme and the regulation of LDL cholesterol receptor numbers (34) . However, other mechanisms are likely to be involved and require additional investigation.
Concern has been expressed that GH administration in children and adolescents may cause or exacerbate, in predisposed individuals, type 2 diabetes mellitus (35) . The effect of GH treatment in adults with GHD on glucose metabolism is still a matter of debate. Most short-term studies have reported a deterioration of insulin sensitivity, whereas longterm studies suggested that, after an initial worsening, insulin sensitivity returned toward baseline values (36) . Children with GHD do not have insulin resistance at baseline; on the contrary, they have in infancy a tendency toward fasting hypoglycemia, whereas susceptibility to hypoglycemia diminishes with age and paradoxically GH-deficient adults may show insulin resistance even before GH replacement therapy. The effect of GH therapy on glucose metabolism in children with GHD has not been extensively investigated. Previous studies in short children have shown that short-term GH replacement was associated with development of insulin resistance and peripheral hyperinsulinemia, as measured by the hyperglycemic clamp technique or using oral glucose tolerance testing, even if insulin levels remained within the physiological range of normal control children (37, 38) . In short small-for-gestational-age children, GH replacement induces high fasting insulin levels with normal glucose levels, suggesting insulin resistance in these patients. However, 6 months after GH discontinuation, insulin levels returned to normal values compared with a control group (39) . No case of impaired glucose tolerance or diabetes was re- severe GHD compared with children with partial GHD and controls before and during 2 yr of GH therapy. *, P Ͻ 0.003 analyzing the effect of GH treatment during the study in the group with partial GHD. §, P Ͻ 0.02 comparing children with partial GHD vs. controls after 2 yr of follow-up.
corded in a large group of 128 GHD children treated with GH for a period of 6 yr, but a significant decrease in insulin sensitivity was detected during the first year of GH therapy (40) .
In the present study, we observed a mild increase in insulin resistance after 2 yr of GH treatment, especially in children with partial GHD who were receiving a slightly higher dose of GH. However, additional follow-up is necessary to evaluate whether insulin sensitivity will continue to worsen as an effect of GH therapy, or this mild increase may instead represent a component of the anabolic process of somatic development as is clearly evident in puberty.
In conclusion, GHD in children is associated with a significantly reduced cardiac size and with a normal cardiac function. Two years of GH replacement normalizes cardiac morphology and does not modify cardiac function. GHD is not associated with a clear-cut impairment of lipid profile, but 2 yr of GH replacement therapy exerts a beneficial effect on it by reducing total cholesterol and AI. On the contrary, a trend toward an increase in insulin resistance is observed during GH treatment. The potential long-term negative effect of insulin resistance determined by GH replacement on cardiovascular morbidity is still to be determined.
